This is consistent with the observation that HER2-positive patients exhibited the highest PAK4 expression among the PAM50 and IC10 breast cancer subtypes and also consistent with the strong correlation observed between PAK4 expression and HER2 signaling in the METABRIC dataset. This evidence concerns the gene PAK4 and breast cancer.